ASCO Value Framework Should Allow For Customization, Drug Firms Urge
This article was originally published in The Pink Sheet Daily
Executive Summary
In comments, the Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization outline long lists of recommended changes in the American Society for Clinical Oncology’s proposed framework for valuing cancer drugs.